MA38192B1 - Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7 - Google Patents

Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7

Info

Publication number
MA38192B1
MA38192B1 MA38192A MA38192A MA38192B1 MA 38192 B1 MA38192 B1 MA 38192B1 MA 38192 A MA38192 A MA 38192A MA 38192 A MA38192 A MA 38192A MA 38192 B1 MA38192 B1 MA 38192B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
indole derivatives
derivatives used
carboxamide indole
carboxamide
Prior art date
Application number
MA38192A
Other languages
English (en)
Other versions
MA38192A1 (fr
Inventor
Kurt Hilpert
Francis Hubler
Thierry Kimmerlin
Dorte Renneberg
Simon Stamm
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA38192A1 publication Critical patent/MA38192A1/fr
Publication of MA38192B1 publication Critical patent/MA38192B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

L'invention concerne des dérivés d'indole carboxamide de formule (i), dans laquelle r1, r 2, r 3, r 4, r5 et r6 ont la signification indiquée dans la description, leur préparation et leur utilisation en tant que composés pharmaceutiquement actifs
MA38192A 2012-12-12 2013-12-11 Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7 MA38192B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12196711 2012-12-12
PCT/IB2013/060794 WO2014091415A1 (fr) 2012-12-12 2013-12-11 Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7

Publications (2)

Publication Number Publication Date
MA38192A1 MA38192A1 (fr) 2017-03-31
MA38192B1 true MA38192B1 (fr) 2017-11-30

Family

ID=47325947

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38192A MA38192B1 (fr) 2012-12-12 2013-12-11 Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7

Country Status (21)

Country Link
US (1) US9718774B2 (fr)
EP (1) EP2931717B1 (fr)
JP (1) JP6295269B2 (fr)
KR (1) KR102232742B1 (fr)
CN (1) CN104812749B (fr)
AR (1) AR093921A1 (fr)
AU (1) AU2013356850B2 (fr)
BR (1) BR112015013463B1 (fr)
CA (1) CA2890886C (fr)
CL (1) CL2015001529A1 (fr)
EA (1) EA029644B1 (fr)
ES (1) ES2618056T3 (fr)
IL (1) IL239295A0 (fr)
MA (1) MA38192B1 (fr)
MX (1) MX368044B (fr)
PH (1) PH12015501339A1 (fr)
PL (1) PL2931717T3 (fr)
SG (1) SG11201504369SA (fr)
TW (1) TWI612034B (fr)
WO (1) WO2014091415A1 (fr)
ZA (1) ZA201504974B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687860B (zh) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7
CA2896790C (fr) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Derives d'amides heterocycliques utilises comme antagonistes du recepteur p2x7
EP2905282A1 (fr) * 2014-02-05 2015-08-12 AXXAM S.p.A. Thiazole ou oxazole substituée en tant qu'antagonistes du récepteur P2X7
US10119405B2 (en) 2015-12-21 2018-11-06 General Electric Company Cooling circuit for a multi-wall blade
US10060269B2 (en) 2015-12-21 2018-08-28 General Electric Company Cooling circuits for a multi-wall blade
US10208608B2 (en) 2016-08-18 2019-02-19 General Electric Company Cooling circuit for a multi-wall blade
US10221696B2 (en) 2016-08-18 2019-03-05 General Electric Company Cooling circuit for a multi-wall blade
US10227877B2 (en) 2016-08-18 2019-03-12 General Electric Company Cooling circuit for a multi-wall blade
US10267162B2 (en) 2016-08-18 2019-04-23 General Electric Company Platform core feed for a multi-wall blade
US10208607B2 (en) 2016-08-18 2019-02-19 General Electric Company Cooling circuit for a multi-wall blade
EP3290416A1 (fr) * 2016-08-31 2018-03-07 AXXAM S.p.A. Dérivés de n-[2-(4-phénoxypipéridin-1-yl)-2-(1,3-thiazol-5-yl)éthyl]benzamide et n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)éthyl]benzamide substitués et leur utilisation en tant qu'antagoniste du récepteur p2x7
AU2018236233A1 (en) * 2017-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Small molecule sensitization of BAX activation for induction of cell death
CN111072505A (zh) * 2019-12-27 2020-04-28 合肥华方医药科技有限公司 一种文拉法辛杂质的制备方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CZ20013608A3 (cs) 1999-04-09 2002-05-15 Astrazeneca Ab Adamantanové deriváty
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (fr) 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
JP2006513205A (ja) 2002-12-31 2006-04-20 ファイザー・プロダクツ・インク Ｐ２ｘ７受容体のベンズアミド阻害剤
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
ATE355273T1 (de) 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
CA2565211A1 (fr) * 2004-04-29 2005-11-24 Abbott Laboratories Analogues d'amino-tetrazoles et methodes d'utilisation
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2006080884A1 (fr) 2005-01-27 2006-08-03 Astrazeneca Ab Nouveaux composes biaromatiques, inhibiteurs du recepteur p2x7
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2007055374A1 (fr) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation Agent therapeutique pour l'osteoporose
CA2645551C (fr) 2006-03-16 2016-06-28 Renovis, Inc. Composes de bicycloheteroaryle en tant que modulateurs de p2x7 et leurs utilisations
DK2001474T3 (en) 2006-03-16 2016-05-09 Second Genome Inc BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF
WO2007109201A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
CA2645652A1 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composes de bicycloheteroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
US20100298285A1 (en) 2006-03-16 2010-11-25 Kelly Michael G Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
DE602007010781D1 (de) 2006-06-06 2011-01-05 Glaxo Group Ltd N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
GB0611154D0 (en) 2006-06-06 2006-07-19 Glaxo Group Ltd Novel receptor antagonists and their methods of use
MX2009000117A (es) 2006-07-06 2009-01-23 Glaxo Group Ltd N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.
EP2591675A1 (fr) 2006-11-27 2013-05-15 H. Lundbeck A/S Dérivés d'hétéroaryle et d'amide
TW200838516A (en) 2007-01-31 2008-10-01 Merck & Co Inc Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2010520875A (ja) 2007-03-09 2010-06-17 レノビス， インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用
CA2680761A1 (fr) 2007-03-22 2008-09-25 Astrazeneca Ab Derives de quinoleine destines au traitement de maladies inflammatoires
GB0705882D0 (en) 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
EP2139858A1 (fr) 2007-03-28 2010-01-06 Glaxo Group Limited Dérivés pipéridone carboxamide comme modulateurs du p2x7
WO2008119685A2 (fr) 2007-03-29 2008-10-09 Glaxo Group Limited Dérivés d'oxazolidine et de morpholine carboxamide comme modulateurs de p2x7
MX2009010759A (es) 2007-04-03 2009-10-28 Glaxo Group Ltd Derivados de carboxamida imidazolidina como modulares de p2x7.
WO2008124153A1 (fr) 2007-04-10 2008-10-16 H. Lundbeck A/S Analogues d'heteroaryl-amides utilises en tant qu'antagonistes de p2x7
US20100056595A1 (en) 2007-04-11 2010-03-04 Glaxo Group Limited Pyrazole Derivatives as P2X7 Modulators
US20110046137A1 (en) 2007-05-10 2011-02-24 Glaxo Group Limited Pyrazole Derivatives as P2X7 Modulators
HRP20151052T1 (xx) 2007-07-19 2015-11-06 H. Lundbeck A/S Peteroäślani heterocikliäśki amidi i srodne tvari
CA2691512A1 (fr) * 2007-08-10 2009-02-19 H. Lundbeck A/S Analogues d'heteroarylamides
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
WO2009074518A1 (fr) 2007-12-12 2009-06-18 Glaxo Group Limited Combinaisons formées de modulateurs au prolinamide du récepteur p2x7 et d'autres agents thérapeutiques
GB0724258D0 (en) 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
GB0724625D0 (en) 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
US20100292295A1 (en) 2007-12-18 2010-11-18 Glaxo Group Limited 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
WO2009108551A2 (fr) 2008-02-25 2009-09-03 H. Lundbeck A/S Analogues d’hétéroarylamide
BRPI0910034B1 (pt) * 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
KR101598397B1 (ko) * 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
US20120157494A1 (en) 2010-12-16 2012-06-21 Harris Iii Ralph New Isoindolyl compounds
US20140073651A1 (en) 2011-02-22 2014-03-13 Actelion Pharmaceuticals Ltd. Benzamide derivatives as p2x7 receptor antagonists
WO2012163792A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
CN103687860B (zh) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
TW201427947A (zh) 2012-10-12 2014-07-16 Lundbeck & Co As H 環狀胺
TWI598325B (zh) 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 苯甲醯胺類
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7
CA2896790C (fr) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Derives d'amides heterocycliques utilises comme antagonistes du recepteur p2x7

Also Published As

Publication number Publication date
AU2013356850A1 (en) 2015-07-30
SG11201504369SA (en) 2015-07-30
BR112015013463A2 (pt) 2017-11-14
MX368044B (es) 2019-09-17
JP6295269B2 (ja) 2018-03-14
KR102232742B1 (ko) 2021-03-26
JP2016508967A (ja) 2016-03-24
CA2890886A1 (fr) 2014-06-19
CN104812749A (zh) 2015-07-29
BR112015013463A8 (pt) 2017-12-26
US20150322008A1 (en) 2015-11-12
CA2890886C (fr) 2020-10-27
MA38192A1 (fr) 2017-03-31
EA201500628A1 (ru) 2015-11-30
EP2931717B1 (fr) 2016-12-07
TW201427944A (zh) 2014-07-16
EP2931717A1 (fr) 2015-10-21
MX2015007493A (es) 2015-09-04
PH12015501339A1 (en) 2015-09-02
KR20150093229A (ko) 2015-08-17
TWI612034B (zh) 2018-01-21
IL239295A0 (en) 2015-07-30
EA029644B1 (ru) 2018-04-30
CN104812749B (zh) 2016-12-14
US9718774B2 (en) 2017-08-01
PL2931717T3 (pl) 2017-05-31
CL2015001529A1 (es) 2015-09-25
ZA201504974B (en) 2017-11-29
ES2618056T3 (es) 2017-06-20
BR112015013463B1 (pt) 2022-06-14
AR093921A1 (es) 2015-06-24
WO2014091415A1 (fr) 2014-06-19
AU2013356850B2 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
MA38192A1 (fr) Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA35905B1 (fr) Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens
MA37990B1 (fr) Benzamides
CR20140566A (es) 7h-pirrolo[2,3-d]pirimidinas 4-(amino-substituidas) novedosas como inhibidores de lrrk2
MX375978B (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
MY169986A (en) Benzimidazole-proline derivatives
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
EA201992679A1 (ru) N-замещенные индольные производные
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA41337A (fr) Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
CY1119449T1 (el) Ενωσεις 1,2,4-τριαζολο|4,3-α]πυριδινης και η χρηση αυτων ως θετικων αλλοστερiκων ρυθμιστων των υποδοχεων mglur2
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MA34578B1 (fr) Composés de tétrahydrofuranyl disubstitués en tant qu'antagonistes du récepteur de la bradykinine b1
MA40110B2 (fr) Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines